Ethos Financial Group LLC Invests $122,000 in Boston Scientific Co. (NYSE:BSX)

Ethos Financial Group LLC acquired a new position in shares of Boston Scientific Co. (NYSE:BSX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,369 shares of the medical equipment provider’s stock, valued at approximately $122,000.

Several other hedge funds have also made changes to their positions in the business. Adero Partners LLC boosted its holdings in shares of Boston Scientific by 3.3% during the fourth quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider’s stock worth $334,000 after purchasing an additional 120 shares during the last quarter. Grove Bank & Trust raised its position in shares of Boston Scientific by 4.4% in the 4th quarter. Grove Bank & Trust now owns 2,923 shares of the medical equipment provider’s stock worth $261,000 after buying an additional 122 shares during the period. PFG Investments LLC raised its position in shares of Boston Scientific by 1.6% in the 4th quarter. PFG Investments LLC now owns 8,113 shares of the medical equipment provider’s stock worth $725,000 after buying an additional 125 shares during the period. Stonegate Investment Group LLC raised its position in shares of Boston Scientific by 1.6% in the 4th quarter. Stonegate Investment Group LLC now owns 7,827 shares of the medical equipment provider’s stock worth $699,000 after buying an additional 126 shares during the period. Finally, Ashton Thomas Securities LLC raised its position in shares of Boston Scientific by 1.3% in the 3rd quarter. Ashton Thomas Securities LLC now owns 9,968 shares of the medical equipment provider’s stock worth $835,000 after buying an additional 129 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Down 1.6 %

NYSE:BSX opened at $99.15 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The business’s 50 day moving average is $100.45 and its two-hundred day moving average is $91.10. Boston Scientific Co. has a 52 week low of $65.52 and a 52 week high of $107.17. The company has a market cap of $146.33 billion, a PE ratio of 79.32, a P/E/G ratio of 2.79 and a beta of 0.80.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, analysts predict that Boston Scientific Co. will post 2.85 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on BSX shares. JPMorgan Chase & Co. increased their target price on Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Royal Bank of Canada increased their target price on Boston Scientific from $105.00 to $116.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Morgan Stanley increased their target price on Boston Scientific from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. UBS Group raised their price objective on Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Finally, Stifel Nicolaus upped their target price on Boston Scientific from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $108.91.

Insiders Place Their Bets

In other news, EVP John Bradley Sorenson sold 1,201 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $106.31, for a total transaction of $127,678.31. Following the sale, the executive vice president now directly owns 25,443 shares in the company, valued at approximately $2,704,845.33. This represents a 4.51 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward J. Ludwig sold 12,000 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $105.48, for a total value of $1,265,760.00. Following the sale, the director now owns 24,398 shares in the company, valued at $2,573,501.04. The trade was a 32.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 137,322 shares of company stock valued at $14,321,068 in the last quarter. Insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.